Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a feasibility study at Queen Mary Hospital to see if patient-specific 3D-bioprinted liver models can guide adjuvant therapy after curative liver resection for HCC. Biomimetic “Liver-in-Cube” models are created from each patient’s tissue to screen potential treatments and identify the most effective option. The study is non-randomised, open-label, and prospective, enrolling about 20 adults over five years. The primary aim is to determine whether this approach can inform personalized post-surgical therapy to reduce recurrence. It is a single-center study led by The University of Hong Kong.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years at the time of screening
* Diagnosis of HCC
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
* With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery - Meet any item indicating higher risk of tumour recurrence: any tumour size ≥ 5cm, number of tumour ≥ 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation
* No prior systemic therapy for HCC
* No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate \> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer
* Willing and able to provide written informed consent for the collection and usage of biological samples

Exclusion Criteria:

* Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc.
* Fail to give consent or refusal to take part in the study
* Child-Pugh class C liver cirrhosis
* Receipt of any prior systemic therapy for HCC

Where it's running

• Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Albert Chan
• Email: hbptrial@hku.hk
• Phone: +852 2255 6646

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TACE plus SBRT before liver transplant for hepatocellular carcinoma

  This study tests whether adding SBRT to standard TACE helps liver transplant patients with hepatocellular carcinoma see better outcomes.

  Recruiting AIO-Studien-gGmbH · München · NCT07924943

• Real-world view of systemic therapies for advanced HCC at a single center

  This study looks at how patients with advanced hepatocellular carcinoma respond to systemic treatments in real-world practice at Mansoura University Hospitals.

  Recruiting Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07814014

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.